Does the media prefer CPRX or ELAN?

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 3 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Elanco Animal Health's score of 0.78 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CPRX or AXSM?

In the previous week, Axsome Therapeutics had 10 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Axsome Therapeutics and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Axsome Therapeutics' score of 0.76 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SMMT or CPRX?

In the previous week, Summit Therapeutics and Summit Therapeutics both had 3 articles in the media. Summit Therapeutics' average media sentiment score of 1.67 beat Catalyst Pharmaceuticals' score of 1.49 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABVX or CPRX?

In the previous week, Abivax had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Abivax and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Abivax's score of 0.81 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RDY or CPRX?

Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Catalyst Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.56

Does the media favor RDY or CPRX?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Dr. Reddy's Laboratories and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Dr. Reddy's Laboratories' score of 0.11 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Catalyst Pharmaceuticals (CPRX) Competitors

$31.49 +0.01 (+0.03%)

Closing price 04:00 PM Eastern

Extended Trading

$31.51 +0.02 (+0.06%)

As of 06:18 PM Eastern

Compare

CPRX vs. ELAN, AXSM, SMMT, ABVX, and RDY

Should you buy Catalyst Pharmaceuticals stock or one of its competitors? MarketBeat compares Catalyst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Catalyst Pharmaceuticals include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), Abivax (ABVX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Elanco Animal Health's net margin of -4.95%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Elanco Animal Health	-4.95%	7.42%	3.66%

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Elanco Animal Health	$4.72B	2.71	-$232M	-$0.50	N/A

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 3 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Elanco Animal Health's score of 0.78 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, indicating a potential upside of 1.62%. Elanco Animal Health has a consensus target price of $28.55, indicating a potential upside of 11.68%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Catalyst Pharmaceuticals beats Elanco Animal Health on 10 of the 16 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Axsome Therapeutics had 10 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Axsome Therapeutics and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Axsome Therapeutics' score of 0.76 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Axsome Therapeutics' net margin of -26.59%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Axsome Therapeutics has a consensus target price of $259.05, suggesting a potential upside of 10.11%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Axsome Therapeutics	$638.50M	18.96	-$183.17M	-$3.73	N/A

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Summit Therapeutics presently has a consensus price target of $26.97, suggesting a potential upside of 74.36%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 1.62%. Given Summit Therapeutics' higher probable upside, equities analysts clearly believe Summit Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Summit Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Summit Therapeutics and Summit Therapeutics both had 3 articles in the media. Summit Therapeutics' average media sentiment score of 1.67 beat Catalyst Pharmaceuticals' score of 1.49 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Catalyst Pharmaceuticals beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Abivax?

Abivax (NASDAQ:ABVX) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Catalyst Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Abivax's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

47.9% of Abivax shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Abivax currently has a consensus target price of $148.54, indicating a potential upside of 10.10%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.62%. Given Abivax's stronger consensus rating and higher possible upside, research analysts plainly believe Abivax is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

In the previous week, Abivax had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Abivax and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Abivax's score of 0.81 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Abivax on 11 of the 16 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Dr. Reddy's Laboratories and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Dr. Reddy's Laboratories' score of 0.11 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.00	$456M	$0.58	22.15
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Dr. Reddy's Laboratories' net margin of 12.90%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Summary

Catalyst Pharmaceuticals beats Dr. Reddy's Laboratories on 13 of the 17 factors compared between the two stocks.

Get Catalyst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPRX vs. The Competition

Export

Metric	Catalyst Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.86B	$2.98B	$6.73B	$12.53B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	18.10	18.77	27.01	24.37
Price / Sales	6.46	825.10	584.48	116.81
Price / Cash	10.77	56.80	29.22	49.36
Price / Book	4.06	4.24	10.81	6.34
Net Income	$214.33M	$64.26M	$3.58B	$330.89M
7 Day Performance	N/A	-3.40%	-2.24%	-1.09%
1 Month Performance	0.41%	2.40%	3.12%	-0.49%
1 Year Performance	45.65%	20.40%	26.33%	19.87%

Catalyst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPRX Catalyst Pharmaceuticals	3.8852 of 5 stars	$31.49 +0.0%	$32.00 +1.6%	+44.3%	$3.86B	$596.96M	18.10	80	Positive News High Trading Volume
ELAN Elanco Animal Health	3.9357 of 5 stars	$25.13 +1.2%	$28.55 +13.6%	+68.7%	$12.40B	$4.72B	N/A	9,400
AXSM Axsome Therapeutics	3.2928 of 5 stars	$228.28 -2.4%	$259.05 +13.5%	+109.5%	$12.03B	$638.50M	N/A	380
SMMT Summit Therapeutics	3.6859 of 5 stars	$15.30 +0.3%	$26.97 +76.3%	-38.8%	$11.84B	N/A	N/A	110	Positive News
ABVX Abivax	2.1552 of 5 stars	$135.98 -2.8%	$148.54 +9.2%	+1,544.3%	$11.16B	N/A	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPRX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Catalyst Pharmaceuticals compare to Abivax?

Summary

How does Catalyst Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ELAN, AXSM, SMMT, ABVX, and RDY

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Do insiders and institutionals believe in CPRX or ELAN?

Is CPRX or ELAN more profitable?

Which has preferable valuation and earnings, CPRX or ELAN?

Which has more risk & volatility, CPRX or ELAN?

Does the media prefer CPRX or ELAN?

Do analysts recommend CPRX or ELAN?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Does the media prefer CPRX or AXSM?

Is CPRX or AXSM more profitable?

Do analysts recommend CPRX or AXSM?

Do institutionals and insiders hold more shares of CPRX or AXSM?

Which has higher valuation and earnings, CPRX or AXSM?

Which has more volatility and risk, CPRX or AXSM?

Summary

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Do analysts rate SMMT or CPRX?

Is SMMT or CPRX more profitable?

Which has higher earnings and valuation, SMMT or CPRX?

Which has more volatility and risk, SMMT or CPRX?

Do insiders and institutionals have more ownership in SMMT or CPRX?

Does the media refer more to SMMT or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to Abivax?

Which has higher earnings & valuation, ABVX or CPRX?

Is ABVX or CPRX more profitable?

Do insiders and institutionals hold more shares of ABVX or CPRX?

Do analysts recommend ABVX or CPRX?

Does the media refer more to ABVX or CPRX?

Which has more volatility & risk, ABVX or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to Dr. Reddy's Laboratories?

Do insiders & institutionals hold more shares of RDY or CPRX?

Does the media favor RDY or CPRX?

Which has more volatility and risk, RDY or CPRX?

Which has stronger earnings & valuation, RDY or CPRX?

Do analysts recommend RDY or CPRX?

Is RDY or CPRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools